Management of severe retinopathy of prematurity in Jaffna
Abstract
Introduction and objectives: Treatment of Retinopathy of Prematurity (ROP) is revolutionized by the use of Anti-Vascular Endothelial Growth Factor agents over the last decade. This study describes the results of the treatment in the newest paediatric ophthalmology unit in Sri Lanka- Teaching hospital, Jaffna. Methods: Retrospective analysis of the ROP screening and treatment data at the paediatric ophthalmology unit at teaching hospital was carried out. All the screening and treatment sessions were carried out under topical anaesthesia. Out of the 118 babies who underwent screening examinations, 12 babies had severe ROP requiring treatment with intravitreal injection of Bevacizumab. In conclusion intravitreal injection of Bevacizumab is very successful in managing severe Zone 1 and Zone 2 ROP although prolong follow up is mandatory to detect recurrences of ROP.
DOI: https://doi.org/10.4038/jmj.v30i2.19 | Journal eISSN: 2651-0200
Language: English
Page range: 10 - 15
Published on: Dec 28, 2018
Published by: The Jaffna Medical Association
In partnership with: Paradigm Publishing Services
© 2018 H. Abeysekera, S. T. S. Chandrakumar, M. Malaravan, L. Gurusinghe, S. Jeyabalan, Rajima Srinani, K. Vicknan, A. Joseph, B. Gajalaksan, published by The Jaffna Medical Association
This work is licensed under the Creative Commons Attribution 4.0 License.